AKO Capital LLP Has $210.43 Million Holdings in GRIFOLS S A/S (GRFS)

AKO Capital LLP trimmed its position in GRIFOLS S A/S (NASDAQ:GRFS) by 8.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,846,971 shares of the biotechnology company’s stock after selling 912,666 shares during the quarter. GRIFOLS S A/S makes up approximately 10.7% of AKO Capital LLP’s portfolio, making the stock its 2nd largest position. AKO Capital LLP owned approximately 1.44% of GRIFOLS S A/S worth $210,430,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. First Trust Advisors LP lifted its position in shares of GRIFOLS S A/S by 85.7% in the third quarter. First Trust Advisors LP now owns 4,634,749 shares of the biotechnology company’s stock worth $99,045,000 after purchasing an additional 2,139,441 shares in the last quarter. Vaughan Nelson Investment Management L.P. lifted its position in shares of GRIFOLS S A/S by 5.1% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 3,021,901 shares of the biotechnology company’s stock worth $64,971,000 after purchasing an additional 147,715 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of GRIFOLS S A/S by 38,886.6% in the second quarter. SG Americas Securities LLC now owns 3,001,189 shares of the biotechnology company’s stock worth $64,526,000 after purchasing an additional 2,993,491 shares in the last quarter. Engadine Partners LLP lifted its position in shares of GRIFOLS S A/S by 18.0% in the second quarter. Engadine Partners LLP now owns 2,906,319 shares of the biotechnology company’s stock worth $62,486,000 after purchasing an additional 443,386 shares in the last quarter. Finally, Gladstone Capital Management LLP lifted its position in shares of GRIFOLS S A/S by 22.1% in the second quarter. Gladstone Capital Management LLP now owns 1,375,539 shares of the biotechnology company’s stock worth $29,299,000 after purchasing an additional 248,850 shares in the last quarter. Institutional investors own 21.35% of the company’s stock.

A number of research firms have recently issued reports on GRFS. Zacks Investment Research raised shares of GRIFOLS S A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 1st. BidaskClub lowered shares of GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research report on Friday, July 13th. UBS Group lowered shares of GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 3rd. Santander raised shares of GRIFOLS S A/S from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 30th. Finally, Berenberg Bank raised shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. GRIFOLS S A/S presently has a consensus rating of “Hold” and a consensus target price of $21.50.

NASDAQ GRFS opened at $21.21 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.78 and a debt-to-equity ratio of 1.47. The company has a market capitalization of $14.29 billion, a PE ratio of 19.28, a P/E/G ratio of 1.48 and a beta of 1.18. GRIFOLS S A/S has a 52-week low of $17.47 and a 52-week high of $25.18.

The firm also recently disclosed a special dividend, which will be paid on Tuesday, December 11th. Investors of record on Monday, December 3rd will be given a dividend of $0.2283 per share. This represents a yield of 2.25%. The ex-dividend date is Friday, November 30th. This is a positive change from GRIFOLS S A/S’s previous special dividend of $0.01. GRIFOLS S A/S’s dividend payout ratio (DPR) is presently 35.45%.

WARNING: “AKO Capital LLP Has $210.43 Million Holdings in GRIFOLS S A/S (GRFS)” was first reported by WKRB News and is the property of of WKRB News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/09/ako-capital-llp-has-210-43-million-holdings-in-grifols-s-a-s-grfs.html.

GRIFOLS S A/S Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Recommended Story: How does inflation affect different investments?

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply